| Clinical data | |
|---|---|
| Other names | 3,4-Ethylenedioxyamphetamine; EDA; EDA-6; α-Methyl-1,4-benzodioxan-6-ethylamine |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C11H15NO2 |
| Molar mass | 193.246 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
3,4-Ethylenedioxyamphetamine (EDA), also known asEDA-6, is adrug of thephenethylamine,amphetamine, andEDxx families related to3,4-methylenedioxyamphetamine (MDA).[1] It is closely related toanalogues including3,4-ethylenedioxymethamphetamine (EDMA),3,4-ethylidenedioxyamphetamine (EIDA), and3,4-isopropylidenedioxyamphetamine (IDA).[1][2] EDMA, theN-methylated analogue of EDA, is known to be aserotonin–norepinephrine–dopamine releasing agent (SNDRA).[3] According toAlexander Shulgin however, the drug only produced limitedpsychoactive effects in humans at doses in the range of 150 to 250 mg.[4][1]
Thispsychoactive drug-related article is astub. You can help Wikipedia byexpanding it. |